Dr. Febbo Explains the Oncotype DX Genomic Prostate Score

Phil Febbo, MD
Published Online: Monday, Mar 06, 2017



Phil Febbo, MD, chief medical officer, Genomic Health, explains the Oncotype DX Genomic Prostate Score (GPS) for patients with clinically low-risk prostate cancer.

The Oncotype DX GPS was developed to predict disease aggressiveness to aid in the decision of whether a patient undergoes active surveillance or definitive treatment, says Febbo.

Results from a clinical validation study, conducted in collaboration with Kaiser Permanente Northern California, showed that this test is a strong predictor of biochemical recurrence and rise in prostate-specific antigen (PSA) in patients following surgery.

As of Feburary 2017, 22 clinical trials involving more than 4200 patients with prostate cancer have been conducted.
 


Phil Febbo, MD, chief medical officer, Genomic Health, explains the Oncotype DX Genomic Prostate Score (GPS) for patients with clinically low-risk prostate cancer.

The Oncotype DX GPS was developed to predict disease aggressiveness to aid in the decision of whether a patient undergoes active surveillance or definitive treatment, says Febbo.

Results from a clinical validation study, conducted in collaboration with Kaiser Permanente Northern California, showed that this test is a strong predictor of biochemical recurrence and rise in prostate-specific antigen (PSA) in patients following surgery.

As of Feburary 2017, 22 clinical trials involving more than 4200 patients with prostate cancer have been conducted.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Genitourinary CancersJul 28, 20171.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
$emailPop$